U.S. Food and Drug Administration approves CSL’s HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B

  • This historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy and generates elevated and sustained factor IX levels for years after a one-time infusion
  • With the approval of HEMGENIX, CSL now offers an even more comprehensive portfolio of treatments for people living with hemophilia B, ushering in a new era of treatment options 

SOURCE

Continue reading

Ultrasound activated microbubbles enhance the activity of standard of care therapeutics in pancreatic cancer

PHOENIX, Arizona and OSLO, Norway — November 21, 2022 — Scientists at the Phoenix-based Translational Genomics Research Institute (TGen), part of City of Hope, and EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), a Norwegian clinical stage precision health company, today report that the ultrasound based Acoustic Cluster Therapy (ACT®) significantly enhanced the antitumor efficacy of standard care therapies in a preclinical model for pancreatic cancer.Continue reading

New Study Identifies Connection Between Diabetes Medications, Multiple Sclerosis

Researchers at the Center for Innovation in Brain Science examined the impact of medication exposure in people with Type 2 diabetes on the risk of developing multiple sclerosis.

The study found that anti-hyperglycemic medications used to treat Type 2 diabetes resulted in an increased risk of multiple sclerosis for people older than 45, particularly among women.Continue reading